The identification of circulating biomarkers such as MPO and FCGR1A could contribute to the development of non-invasive screening tools for early colorectal cancer detection, offering potential clinical benefits through more personalized approaches to colorectal cancer management. This evidence concerns the gene FCGR1A and colorectal cancer.